IRIS
GAUDIO, AGOSTINO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.078
EU - Europa 914
AS - Asia 239
OC - Oceania 1
SA - Sud America 1
Totale 2.233
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.076
IE - Irlanda 326
SE - Svezia 306
CN - Cina 194
DE - Germania 72
IT - Italia 71
UA - Ucraina 60
FI - Finlandia 26
HK - Hong Kong 26
GB - Regno Unito 18
FR - Francia 17
IN - India 14
BE - Belgio 13
NL - Olanda 3
CA - Canada 2
KR - Corea 2
RU - Federazione Russa 2
AU - Australia 1
CL - Cile 1
IR - Iran 1
JP - Giappone 1
VN - Vietnam 1
Totale 2.233
Salva come PNG Salva come JPEG
Città #
Dublin 326
Chandler 239
Nyköping 172
Jacksonville 146
Beijing 67
Ashburn 64
New York 50
Princeton 47
Medford 44
Ann Arbor 37
Dearborn 34
Des Moines 31
Cambridge 30
Bremen 29
Shenyang 22
Messina 18
Boardman 16
Jinan 15
Nanjing 15
Brussels 13
Wilmington 13
Pune 11
Tianjin 11
Seattle 10
Houston 9
San Mateo 9
Hebei 8
Lancaster 8
Central 7
Sheung Shui 7
Strasbourg 7
Falls Church 6
Hangzhou 6
Woodbridge 6
Fuzhou 5
Haikou 5
Taiyuan 5
Zhengzhou 5
Guangzhou 4
Nanchang 4
Clearwater 3
Leawood 3
Los Angeles 3
Ningbo 3
Norwalk 3
Paterno 3
Polverigi 3
Rho 3
Taizhou 3
Auburn Hills 2
Bari 2
Cairo Montenotte 2
Catania 2
Changsha 2
Fiumefreddo Di Sicilia 2
Helsinki 2
Itasca 2
Jeffries 2
Lanzhou 2
Milan 2
Muespach 2
Nuremberg 2
Regalbuto 2
Scandicci 2
Turin 2
Washington 2
Ardabil 1
Augusta 1
Biancavilla 1
Chaoyang 1
Chicago 1
Cupertino 1
Den Haag 1
Edinburgh 1
Fremont 1
Hanover 1
Hefei 1
Ho Chi Minh City 1
Milazzo 1
Monmouth Junction 1
Mountain View 1
Mumbai 1
Novokuznetsk 1
Ottawa 1
Reno 1
Riva 1
Rome 1
Tappahannock 1
Tomsk 1
Vancouver 1
Totale 1.646
Salva come PNG Salva come JPEG
Nome #
Bisphosphonates in the treatment of thalassemia-associated osteoporosis. 82
Long-term hemostatic effects of cholesterol-lowering therapy with atorvastatin 81
Effects of strontium ranelate on bone mass and bone turnover in women with thalassemia major-related osteoporosis 80
AB0819 HANDGRIP STRENGTH PREDICTS HIGH FRACTURE RISK IN PATIENTS WITH TYPE 2 DIABETES MELLITUS 68
Effects of the phytoestrogen genistein on some predictors of cardiovascular risk in osteopenic, postmenopausal women: A two-year randomized, double-blind, placebo-controlled study 65
TRABECULAR BONE SCORE IS PREDICTED BY PHALANGEAL QUANTITATIVE ULTRASOUND IN BREAST CANCER POSTMENOPAUSAL WOMEN RECEIVING AROMATASE INHIBITORS 63
Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: A randomized double-blind placebo-controlled study 59
Bisphosphonates in the treatment of thalassemia-induced osteoporosis 58
Effects of the phytoestrogen genistein on bone metabolism in osteopenic postmenopausal women - A randomized trial 58
Osteoporosis and beta-thalassemia major: Role of the IGF- I/IGFBP-III axis 57
EFFECTS OF DENOSUMAB ON QUANTITATIVE ULTRASOUND AND DUAL-ENERGY X-RAY ABSORPTIOMETRY MEASUREMENTS IN AROMATASE INHIBITOR-TREATED BREAST CANCER WOMEN 57
Effects of the phytoestrogen genistein on hot flushes, endometrium, and vaginal epithelium in postmenopausal women: a 1-year randomized, double-blind, placebo-controlled study 56
Effects of the phytoestrogen genistein on hot flushes, endometrium and vaginal epithelium in postmenopausal women: a 2-year randomized, double-blind, placebo controlled study. 56
Pain in Osteoporosis: From Pathophysiology to Therapeutic Approach 56
EFFECTS OF DENOSUMAB ON QUATITATIVE ULTRASOUND AND DXA MEASUREMENTS IN AROMATASE INHIBITOR-TREATED BREAST CANCER WOMEN 56
OPG and sRANKL serum concentrations in osteopenic, postmenopausal women after 2-year genistein administration. 55
BONE MASS AND BONE TURNOVER IN WOMEN WITH THALASSEMIA MAJOR RELATED OSTEOPOROSIS: EFFECTS OF STRONTIUM RANELATE 55
AB0823 TRABECULAR BONE SCORE AT LUMBAR SPINE IS ASSOCIATED WITH QUANTITATIVE ULTRASOUND MEASUREMENTS AT PHALANGEAL SITE IN BREAST CANCER SURVIVORS RECEIVING AROMATASE INHIBITORS 55
Effect of long-term treatment with Raloxifene on mammary density in postmenopausal women. 54
Randomized, double-blind, placebo-controlled study on effects of raloxifene and hormone replacement therapy on plasma NO concentrations, endothelin-1 levels, and endothelium-dependent vasodilation in postmenopausal women 50
Three-year effectiveness of intravenous pamidronate versus pamidronate plus slow-release sodium fluoride for postmenopausal osteoporosis 50
CORRELATION BETWEEN FAMILY HISTORY OF HYPERTENSION AND HAEMOSTATIC DISORDERS 49
Effects of a long-term treatment with raloxifene on insulin sensitivity in postmenopausal women 49
Metabolic effects of dehydroepiandrosterone replacement therapy in postmenopausal women 49
Effects of the phytoestrogen genistein on hot flushes, endometrium and vaginal epithelium in postmenopausal women: a 2-year randomized, double-blind, placebo-controlled study 48
Hemostasis and fibrinolysis factors in first-degree relatives of patients with type 2 diabetes without hypertension 48
Effects of hormonal replacement therapy on bone metabolism in young adults with beta-thalassemia major 48
Trabecular bone score and quantitative ultrasound measurements in the assessment of bone health in breast cancer survivors assuming aromatase inhibitors 48
Effetti del raloxifene sulla secrezione ipofisaria in post-menopausa 45
HANDGRIP STRENGTH TO DISCRIMINATE HIGH FRACTURE RISK IN TYPE 2 DIABETES MELLITUS PATIENTS 43
Early Changes of VEGF Levels After Zoledronic Acid in Women With Postmenopausal Osteoporosis: A Potential Role of Vitamin D 40
Pharmacological management of severe postmenopausal osteoporosis 39
Menopause modulates homocysteine levels in diabetic and non-diabetic women. 39
VITAMIN D PROMOTES BONE MINERAL DENSITY ACCRUAL AFTER DISCONTINUATION OF ALENDRONATE 39
Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: New pieces of the puzzle 38
Familiar osteopoikilosis: Case report with differential diagnosis and review of the literature 38
Early vascular ageing biomarkers in osteoporotic outpatients: a pilot study 37
ALENDRONATE TAIL EFFECT ON BONE IS MODULATED BY VITAMIN D: A RETROSPECTIVE STUDY IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS 37
Quantitative ultrasound and DXA measurements in aromatase inhibitor-treated breast cancer women receiving denosumab 36
Pathogenesis of Thalassemia Major-Associated Osteoporosis: Review of the Literature and Our Experience 36
Sclerostin is a possible candidate marker of arterial stiffness: Results from a cohort study in Catania 34
Anxiety levels predict bone mineral density in postmenopausal women undergoing oral bisphosphonates: A two-year follow-up 30
Bone health in Duchenne muscular dystrophy: clinical and biochemical correlates 30
Vitamin d boosts alendronate tail effect on bone mineral density in postmenopausal women with osteoporosis 25
null 21
null 21
POS1119 A SINGLE DOSE OF ZOLEDRONATE INDUCES MODIFICATIONS OF SERUM VEGF IN OSTEOPOROTIC POSTMENOPAUSAL WOMEN 16
IMPACT OF ANXIETY LEVELS ON BONE MINERAL DENSITY IN POSTMENOPAUSAL WOMEN TREATED WITH ORAL BIPHOSPHONATES: RESULTS FROM A LONGITUDINAL COHORT STUDY 15
Osteoporosis and Fragility Fractures in Type 2 Diabetes 14
Antihypertensive treatment changes and related clinical outcomes in older hospitalized patients 7
Underdiagnosis and undertreatment of osteoporotic patients admitted in internal medicine wards in Italy between 2010 and 2016 (the REPOSI Register) 6
Clinical and molecular description of the first Italian cohort of 33 subjects with hypophosphatasia 5
Totale 2.301
Salva come PNG Salva come JPEG
Categoria #
all - tutte 8.863
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.863
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20194 0 0 0 0 0 0 0 0 0 0 2 2
2019/2020297 38 23 5 22 4 28 47 32 5 57 33 3
2020/2021207 24 1 64 8 16 30 1 20 0 17 19 7
2021/2022422 1 63 14 7 14 7 49 13 32 79 36 107
2022/2023959 63 110 51 53 79 95 11 63 385 12 23 14
2023/2024255 20 39 16 29 15 81 3 39 0 11 2 0
Totale 2.301